While investigating K-Ras signalling in non-small cell lung cancer, Levallet et al. (2012) identified K-Ras mutations in clinical samples were strongly and frequently associated with positive βIII-tubulin expression. Here, KRAS is linked to non-small cell lung carcinoma.